AI USE CASE
Patent Expiry Lifecycle Strategy Optimizer
Help pharma strategists defend revenue and plan generic entry response using AI-driven patent intelligence.
See if this fits your context, free 7-min diagnostic
Run the diagnostic →What it is
Combines NLP-based patent landscape analysis with predictive analytics on competitor pipelines and market data to optimize lifecycle management decisions. Pharma companies typically face 20-40% revenue erosion within 12 months of loss of exclusivity; this approach can extend branded revenue windows by identifying reformulation, new indication, or authorized generic opportunities 18-36 months in advance. Teams gain structured competitive intelligence from unstructured patent filings, FDA submissions, and pricing data, reducing manual research effort by 50-70%. Outputs feed directly into portfolio investment decisions and generic entry defense playbooks.
Data you need
Historical patent filing data, competitor pipeline databases, FDA/EMA submission records, and product-level market and pricing data spanning at least 5 years.
Required systems
- data warehouse
- erp
Why it works
- Establish a dedicated IP and competitive intelligence data pipeline before model development begins.
- Involve medical affairs, regulatory, and commercial strategy teams early to ensure outputs map to real decision points.
- Build explainability layers so strategists can trace why a specific defense option is ranked highest.
- Run quarterly model retraining cycles aligned with patent filing and regulatory submission calendars.
How this goes wrong
- Patent and competitor pipeline data is incomplete or not systematically collected, making model outputs unreliable.
- Strategic recommendations are not trusted by senior teams if the AI rationale is opaque, low explainability kills adoption.
- Integration with portfolio investment workflows is skipped, leaving outputs as reports that no one acts on.
- Model trained on historical patent landscapes becomes stale as regulatory and IP environments shift rapidly.
When NOT to do this
Do not pursue this if your organisation lacks a structured patent data governance process and a cross-functional strategy team willing to operationalise model outputs, the analysis will sit unused.
Vendors to consider
Sources
Other use cases in this function
This use case is part of a larger Data & AI catalog built from 50+ enterprise transformation programs. Take the free diagnostic to see how it ranks against your specific context.